Pharmacogenomics (PGX) Market Report

Pharmacogenomics (PGX) Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Nov 25, 2019
  • PAGES：139
  • REPORT CODE：GMM393737
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Pharmacogenomics (PGX) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period.

    This report presents the market size and development trends by detailing the Pharmacogenomics (PGX) market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Pharmacogenomics (PGX) market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Pharmacogenomics (PGX) industry and will help you to build a panoramic view of the industrial development.

    Pharmacogenomics (PGX) Market, By Type:

    • Microarray

    • Sequencing

    • Polymerase Chain Reaction

    • Others

    Pharmacogenomics (PGX) Market, By Application:

    • Oncology

    • Cardiology

    • Neurological Disorders

    • Others

    Some of the leading players are as follows:

    • GE Healthcare

    • Illumina, Inc

    • Genset

    • Abbott Laboratories.

    • Transgenomic, Inc

    • Pfizer, Inc

    • GeneTech.

    • 23andMe, Inc.

    • Pathway Genomics.

    • Myriad Genetics, Inc

    • GeneDx.

    • Thermo Fisher Scientific.

    • Affymetrix, Inc.

    • OSI Pharmaceuticals

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Pharmacogenomics (PGX) Market: Technology Type Analysis

    • 4.1 Pharmacogenomics (PGX) Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Pharmacogenomics (PGX) Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Microarray

      • 4.3.2 Sequencing

      • 4.3.3 Polymerase Chain Reaction

      • 4.3.4 Others

    5 Pharmacogenomics (PGX) Market: Product Analysis

    • 5.1 Pharmacogenomics (PGX) Product Market Share Analysis, 2018 & 2026

    • 5.2 Pharmacogenomics (PGX) Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Pharmacogenomics (PGX) Market: Application Analysis

    • 6.1 Pharmacogenomics (PGX) Application Market Share Analysis, 2018 & 2026

    • 6.2 Pharmacogenomics (PGX) Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Oncology

      • 6.3.2 Cardiology

      • 6.3.3 Neurological Disorders

      • 6.3.4 Others

    7 Pharmacogenomics (PGX) Market: Regional Analysis

    • 7.1 Pharmacogenomics (PGX) Regional Market Share Analysis, 2018 & 2026

    • 7.2 Pharmacogenomics (PGX) Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 GE Healthcare

      • 9.1.1 GE Healthcare Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Illumina, Inc

      • 9.2.1 Illumina, Inc Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Genset

      • 9.3.1 Genset Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Abbott Laboratories.

      • 9.4.1 Abbott Laboratories. Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Transgenomic, Inc

      • 9.5.1 Transgenomic, Inc Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Pfizer, Inc

      • 9.6.1 Pfizer, Inc Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 GeneTech.

      • 9.7.1 GeneTech. Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 23andMe, Inc.

      • 9.8.1 23andMe, Inc. Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Pathway Genomics.

      • 9.9.1 Pathway Genomics. Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Myriad Genetics, Inc

      • 9.10.1 Myriad Genetics, Inc Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 GeneDx.

      • 9.11.1 GeneDx. Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Thermo Fisher Scientific.

      • 9.12.1 Thermo Fisher Scientific. Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Affymetrix, Inc.

      • 9.13.1 Affymetrix, Inc. Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 OSI Pharmaceuticals

      • 9.14.1 OSI Pharmaceuticals Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

     

    The List of Tables and Figures (Totals 70 Figures and 131 Tables)

    • Figure Microarray Pharmacogenomics (PGX) market, 2015 - 2026 (USD Million)

    • Figure Sequencing Pharmacogenomics (PGX) market, 2015 - 2026 (USD Million)

    • Figure Polymerase Chain Reaction Pharmacogenomics (PGX) market, 2015 - 2026 (USD Million)

    • Figure Others Pharmacogenomics (PGX) market, 2015 - 2026 (USD Million)

    • Figure Oncology market, 2015 - 2026 (USD Million)

    • Figure Cardiology market, 2015 - 2026 (USD Million)

    • Figure Neurological Disorders market, 2015 - 2026 (USD Million)

    • Figure Others market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Pharmacogenomics (PGX) market, by country, 2015 - 2026 (USD Million)

    • Table North America Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table North America Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table North America Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Canada Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Canada Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Europe Pharmacogenomics (PGX) market, by country, 2015 - 2026 (USD Million)

    • Table Europe Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Europe Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Europe Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Germany Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Germany Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table France Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table France Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Italy Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Italy Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Spain Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Spain Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Pharmacogenomics (PGX) market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table China Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table China Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Japan Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Japan Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table India Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table India Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Pharmacogenomics (PGX) market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table MEA Pharmacogenomics (PGX) market, by country, 2015 - 2026 (USD Million)

    • Table MEA Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table MEA Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table MEA Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Pharmacogenomics (PGX) market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Pharmacogenomics (PGX) market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Pharmacogenomics (PGX) market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table GE Healthcare Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Illumina, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Genset Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Abbott Laboratories. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Transgenomic, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GeneTech. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table 23andMe, Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pathway Genomics. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Myriad Genetics, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GeneDx. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Thermo Fisher Scientific. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Affymetrix, Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table OSI Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US